Please check your internet connection and try again.
# Norepinephrine
## Overview
Norepinephrine is a potent sympathomimetic amine that acts as a vasopressor and inotrope. It primarily stimulates alpha-1 adrenergic receptors, causing vasoconstriction and increasing systemic vascular resistance and blood pressure. It also has some beta-1 adrenergic receptor activity, increasing heart rate and contractility, though this effect is less pronounced than its alpha-1 effects.
## Primary Indications
* Treatment of hypotension (low blood pressure) in patients with shock, including septic shock, cardiogenic shock, and neurogenic shock.
* Restoration and maintenance of adequate blood pressure when other therapeutic measures are insufficient.
## Adult Dosing
* **Initial Dose:** Typically initiated at 2 to 10 mcg/minute via continuous intravenous infusion.
* **Titration:** Dose is titrated to achieve a target mean arterial pressure (MAP) of 65-75 mmHg, or as per local protocol. Doses can be increased up to 30 mcg/minute or higher in refractory hypotension.
* **Maximum Dose:** There is no absolute maximum dose, but higher doses are associated with increased risks and should be carefully considered. Dosing is highly individualized based on patient response and hemodynamic goals.
## Pediatric Dosing
* **Initial Dose:** 0.05 to 0.1 mcg/kg/minute via continuous intravenous infusion.
* **Titration:** Dose can be increased to 1 mcg/kg/minute or higher based on clinical response and hemodynamic goals, as per local protocol.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is usually necessary as the drug is primarily used in critically ill patients where continuous hemodynamic monitoring allows for titration.
* **Hepatic Impairment:** No specific dose adjustment is usually necessary for similar reasons as renal impairment.
## Contraindications
* Hypersensitivity to norepinephrine.
* Should not be used as the sole agent to correct hypotension due to hypovolemia.
## Adverse Effects
* **Cardiovascular:** Arrhythmias (ventricular and atrial), bradycardia (reflex), hypertension, peripheral ischemia, extravasation leading to tissue necrosis.
* **Central Nervous System:** Headache, anxiety, dizziness, confusion.
* **Respiratory:** Dyspnea.
* **Metabolic:** Hyperglycemia.
## Key Drug Interactions
* **Monoamine Oxidase Inhibitors (MAOIs) & Tricyclic Antidepressants (TCAs):** Potentiate the pressor response to norepinephrine, potentially leading to hypertensive crisis. Concurrent use is generally contraindicated or requires extreme caution and dose reduction.
* **Anesthetic Agents:** May increase myocardial irritability and the risk of arrhythmias.
* **Beta-Adrenergic Blockers:** May unmask unopposed alpha-adrenergic effects, leading to severe hypertension.
* **Alpha-Adrenergic Blockers:** May antagonize the pressor effects of norepinephrine.
## Monitoring
* **Hemodynamic parameters:** Blood pressure (MAP), heart rate, central venous pressure (CVP), pulmonary artery pressures (if available).
* **Urine output:** To assess renal perfusion.
* **Lactate levels:** To assess tissue perfusion and response to therapy.
* **ECG:** For arrhythmias.
* **Peripheral perfusion:** Assess for signs of ischemia (e.g., color, temperature, capillary refill).
## Clinical Pearls
* Norepinephrine must be diluted in a compatible intravenous solution (e.g., D5W or NS).
* Administer via a central venous catheter whenever possible to minimize the risk of extravasation and tissue necrosis.
* If extravasation occurs, immediately stop the infusion, aspirate residual drug, and infiltrate the area with phentolamine mesylate.
* Rapidly titrate to the lowest effective dose to achieve hemodynamic goals and minimize adverse effects.
* Continuous ECG monitoring is recommended due to the risk of arrhythmias.
***
*Please verify this information with the most current prescribing information and relevant clinical guidelines.*
